We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study
Read MoreHide Full Article
DICE Therapeutics skyrocketed 62.27% on Oct 11 after the company announced positive top-line data from a phase I study evaluating its lead therapeutic candidate, DC-806, for treating psoriasis.
Shares of DICE Therapeutics have surged 58% in the year-to-date period against the industry’s decline of 27%.
Image Source: Zacks Investment Research
DC-806 is an oral antagonist of the pro-inflammatory signaling cytokine, interleukin-17 (“IL-17”), which is a validated drug target implicated in a variety of autoimmune and inflammatory diseases, including psoriasis.
The phase I study is designed to evaluate the safety and pharmacokinetics (PK) of DC-806 in healthy volunteers and provide early clinical proof-of-concept in psoriasis patients.
The study was conducted in three overlapping cohorts, phase Ia single ascending dose (SAD) and phase Ib multiple ascending dose (MAD) in healthy volunteers, and a proof-of-concept phase Ic in psoriasis patients. The enrollment in the phase I study was completed in July 2022.
The data in all three cohorts of the study exhibited well-tolerability and a favorable safety profile of DC-806 in both the healthy volunteers and psoriasis patients. No serious adverse events were reported.
DC-806 also demonstrated a favorable PK profile with dose-proportional increments in serum concentrations in the volunteers throughout the study. Moreover, in the phase Ib MAD and phase Ic cohorts of the study, DC-806 exhibited clear pharmacodynamic effects in two distinct biomarkers, namely IC50 and IC90,across doses of 175mg QD and 400mg BID, respectively.
DICE intends to submits an investigational new drug application (IND) to the FDA in the first half of 2023, as well as, advance the candidate into a dose-ranging phase IIb study in patients with moderate-to-severe psoriasis.
Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has narrowed from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. The average negative earnings surprise for STSA is 6.83%.
Aridis Pharmaceuticals' loss estimates for 2022 have remained steady at 23 cents over the past 30 days. The loss estimates for 2023 also remained steady at 53 cents per share in the same time frame.
ARDS surpassed earnings in three of the trailing four quarters, missing the same in one. The average negative earnings surprise for Aridis is 238.54%.
Immunocore’s loss per share estimates for 2022 widened from $1.34 to $1.46 in the past 30 days. The same for 2023 has narrowed from $1.78 to $1.65 in the same time frame.
Earnings of Immunocore missed estimates in three of the trailing four quarters, while beating the same in the reaming occasion. The average earnings surprise for IMCR is 33.28%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study
DICE Therapeutics skyrocketed 62.27% on Oct 11 after the company announced positive top-line data from a phase I study evaluating its lead therapeutic candidate, DC-806, for treating psoriasis.
Shares of DICE Therapeutics have surged 58% in the year-to-date period against the industry’s decline of 27%.
Image Source: Zacks Investment Research
DC-806 is an oral antagonist of the pro-inflammatory signaling cytokine, interleukin-17 (“IL-17”), which is a validated drug target implicated in a variety of autoimmune and inflammatory diseases, including psoriasis.
The phase I study is designed to evaluate the safety and pharmacokinetics (PK) of DC-806 in healthy volunteers and provide early clinical proof-of-concept in psoriasis patients.
The study was conducted in three overlapping cohorts, phase Ia single ascending dose (SAD) and phase Ib multiple ascending dose (MAD) in healthy volunteers, and a proof-of-concept phase Ic in psoriasis patients. The enrollment in the phase I study was completed in July 2022.
The data in all three cohorts of the study exhibited well-tolerability and a favorable safety profile of DC-806 in both the healthy volunteers and psoriasis patients. No serious adverse events were reported.
DC-806 also demonstrated a favorable PK profile with dose-proportional increments in serum concentrations in the volunteers throughout the study. Moreover, in the phase Ib MAD and phase Ic cohorts of the study, DC-806 exhibited clear pharmacodynamic effects in two distinct biomarkers, namely IC50 and IC90,across doses of 175mg QD and 400mg BID, respectively.
DICE intends to submits an investigational new drug application (IND) to the FDA in the first half of 2023, as well as, advance the candidate into a dose-ranging phase IIb study in patients with moderate-to-severe psoriasis.
DICE Therapeutics, Inc. Price
DICE Therapeutics, Inc. price | DICE Therapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
DICE Therapeutics currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector include Acadia Pharmaceuticals (ACAD - Free Report) , Aridis Pharmaceuticals (ARDS - Free Report) , and Immunocore (IMCR - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has narrowed from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. The average negative earnings surprise for STSA is 6.83%.
Aridis Pharmaceuticals' loss estimates for 2022 have remained steady at 23 cents over the past 30 days. The loss estimates for 2023 also remained steady at 53 cents per share in the same time frame.
ARDS surpassed earnings in three of the trailing four quarters, missing the same in one. The average negative earnings surprise for Aridis is 238.54%.
Immunocore’s loss per share estimates for 2022 widened from $1.34 to $1.46 in the past 30 days. The same for 2023 has narrowed from $1.78 to $1.65 in the same time frame.
Earnings of Immunocore missed estimates in three of the trailing four quarters, while beating the same in the reaming occasion. The average earnings surprise for IMCR is 33.28%.